blood collection for cell culture and tests.

12 trials

Sponsors

Takimoto Rishu, Goto Shigenori

Conditions

malignant tumornone

Phase 1

Multicenter clinical study of immune-cell therapy in patients with malignant tumors.

RecruitingJPRN-jRCTc030190256

Goto Shigenorimalignant tumor

Start: 2015-10-01Target: 6000Updated: 2026-06-29

Multicenter clinical study of immune-cell therapy in patients with malignant tumors.

RecruitingJPRN-jRCTc030190251

Goto Shigenorimalignant tumor

Start: 2015-10-01Target: 6000Updated: 2026-06-29

Multicenter clinical study of immune-cell therapy in patients with malignant tumors.

RecruitingJPRN-jRCTc030190255

Goto Shigenorimalignant tumor

Start: 2015-10-01Target: 6000Updated: 2026-06-29

Multicenter clinical study of immune-cell therapy in patients with malignant tumors.

RecruitingJPRN-jRCTc030190250

Goto Shigenorimalignant tumor

Start: 2015-10-01Target: 6000Updated: 2026-06-29

Multicenter clinical study of immune-cell therapy in patients with malignant tumors.

RecruitingJPRN-jRCTc030190254

Goto Shigenorimalignant tumor

Start: 2015-10-01Target: 6000Updated: 2026-06-29

Multicenter clinical study of immune-cell therapy in patients with malignant tumors.

Active, not recruitingJPRN-jRCTc030190257

Goto Shigenorimalignant tumor

Start: 2020-10-01Target: 6000Updated: 2026-06-29

Safety evaluation of the preemptive immune-cell therapy against cancer.

RecruitingJPRN-jRCTc030190260

Goto Shigenorinone

Start: 2015-12-15Target: 650Updated: 2026-06-29

Multicenter clinical study of immune-cell therapy in patients with malignant tumors.

RecruitingJPRN-jRCTc030190253

Goto Shigenorimalignant tumor

Start: 2015-10-01Target: 6000Updated: 2026-06-29

Multicenter clinical study of immune-cell therapy in patients with malignant tumors.

RecruitingJPRN-jRCTc030220555

Goto Shigenorimalignant tumor

Start: 2015-10-01Target: 6000Updated: 2026-06-29

Multicenter clinical study of immune-cell therapy in patients with malignant tumors.

RecruitingJPRN-jRCTc030220632

Goto Shigenorimalignant tumor

Start: 2015-10-01Target: 6000Updated: 2026-06-29

Safety evaluation of the preemptive immune-cell therapy against cancer.

RecruitingJPRN-jRCTc030230349

Goto Shigenorinone

Start: 2015-12-15Target: 650Updated: 2026-06-29

Phase 2

DC vaccine with neoantigen for malignant tumor.

RecruitingJPRN-jRCTc030190182

Takimoto Rishumalignant tumor

Start: 2020-01-22Target: 60Updated: 2026-06-29